albumin binding raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-27 and is reviewed periodically as new material appears.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | GHRH receptor agonist |
| Sequence length | 29 amino acids | Derived from human GHRH |
| Molecular weight | About 3368 Da without linker | Albumin-binding form is heavier |
| Appearance | White to off-white lyophilized powder | Common form for research reference material |
| Typical storage | -20 °C or below, desiccated | Protect powder from light and moisture |
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
== Playwrights, screenwriters, producers, and directors == Henry Churchill de Mille (1875), playwright and Georgist; father of film pioneers Cecil B. DeMille and William C. deMille William C. deMille (1900), screenwriter, director, playwright; second president of the Academy of Motion Picture Arts and Sciences; co-founder of the USC School of Cinematic Arts Edgar Allan Woolf (1901), screenwriter, The Wizard of Oz George Middleton (1902), playwright and president of the Dramatists Guild of America Herman Mankiewicz (1917), drama critic for The New Yorker and co-winner of the Academy Award for Best Original Screenplay for Citizen Kane Morrie Ryskind* (1917), winner of the Pulitzer Prize for Drama with George S. Kaufman for Of Thee I Sing and co-writer of The Cocoanuts, Animal Crackers, and A Night at the Opera Sam Spewack (1919), winner of the Tony Award for the book of Kiss Me, Kate Sidney Buchman (1923), screenwriter for Mr. Smith Goes to Washington and winner of the Academy Award for Writing Adapted Screenplay for Here Comes Mr. Jordan Guy Endore (1923), screenwriter for The Story of G.I. Joe Alvah Bessie (1924), screenwriter for Objective, Burma! and one of the Hollywood Ten Ferrin Fraser (1927), radio scriptwriter for Little Orphan Annie and Frank Buck Joseph Mankiewicz (1928), Academy Award-winning writer and director of All About Eve and A Letter to Three Wives Frank S. Nugent (1929), screenwriter for Fort Apache, She Wore a Yellow Ribbon, and The Quiet Man Robert F.
==== STS-118 ==== Caldwell Dyson was assigned to STS-118 on May 17, 2006. It was announced that she would serve as mission specialist 1 on the first flight of Space Shuttle Endeavour after the Columbia disaster. On August 8, 2007, Caldwell Dyson lifted off for the first time on the 119th Space Shuttle flight, the 22nd flight to the station, and the 20th flight for Endeavour. During the mission, she successfully added another truss segment, a new gyroscope and external spare parts platform to the International Space Station. A new system that enables docked shuttles to draw electrical power from the station to extend visits to the outpost was activated successfully. A total of four spacewalks (EVAs) were performed by three crew members. Endeavour carried some 5,000 pounds of equipment and supplies to the station and returned to Earth with some 4,000 pounds of hardware and no-longer-needed equipment. Traveling 5.3 million miles in space, the STS-118 mission was completed in 12 days, 17 hours, 55 minutes and 34 seconds. On day 7 of the flight of STS-118, Caldwell-Dyson celebrated her 38th birthday.
=== Overdose === Overdose is extremely dangerous; cases reported to poison control centers had a 11.9 percent fatality rate between 2010 and 2020. Although the largest number of overdose deaths occurred in the 1910s and 1920s when the chemical was in more widespread industrial use, the substance's use as a dieting aid has caused a number of fatalities in the 21st century: at least 50 overdose deaths were reported worldwide between 2010 and 2020. Although the lowest published fatal ingested dose is 4.3 mg/kg, a typical overdose death occurs at a higher level of exposure, around 20–50 mg/kg. The first symptoms to appear are nausea, vomiting, abdominal pain, and perhaps diarrhea. The typical overdose syndrome seen with DNP and other phenols is a combination of hyperthermia, tachycardia, diaphoresis, and tachypnoea. Because of the heat produced during uncoupling, DNP overdose will overpower the body's attempt to maintain thermal homeostasis and cause an uncontrolled, fatal rise in body temperature up to as high as 44 °C (111 °F). The disruption of metabolism also leads to the accumulation of potassium and phosphate, potentially contributing to toxicity. DNP can cause T wave and ST segment abnormalities; heart muscle, kidney, and liver damage have been found on autopsy. According to an analysis of United Kingdom and United States overdose cases, tachycardia, hyperpyrexia, acidosis, and agitation or confusion are independent predictors of overdose death. There is no antidote to DNP and management strategies are based on expert opinion and case studies.
Sources: en.wikipedia.org
Sumatriptan is structurally similar to the neurotransmitter serotonin (5-HT) and acts as an agonist of the serotonin 5-HT1B, 5-HT1D, and 5-HT1F receptors. Sumatriptan's primary therapeutic effect is related in its inhibition of the release of calcitonin gene-related peptide (CGRP), likely through its 5-HT1D/1B receptor agonist action. This has been substantiated by the efficacy of more recently developed CGRP targeting drugs and antibodies developed for the preventive treatment of migraine. How agonism of the 5-HT1D/1B receptors inhibits CGRP release is not fully understood. CGRP is believed to cause sensitization of trigeminal nociceptive neurons, contributing to the pain experienced in migraine. Sumatriptan is also shown to decrease the activity of the trigeminal nerve, which presumably accounts for sumatriptan's efficacy in treating cluster headaches. The injectable form of the drug has been shown to abort a cluster headache within 30 minutes in 77% of cases. Sumatriptan does not affect oxytocin or vasopressin levels in humans.
== Structure and reactivity == DBNPA is a halogenated cyanoacetamide compound, characterized by the presence of two bromine atoms at the 2,2-position of the carbon backbone. DBNPA contains a cyano (-CN) group and an amide (-CONH2) group attached to a three-carbon chain. The molecular formula is C3H2Br2N2O, with a molecular weight of 241.87 g/mol. DBNPA is highly reactive due to the two electron-withdrawing bromine atoms and a cyano (-CN) group attached to the central carbon backbone. These substituents form a very electron-deficient core, making it highly vulnerable to nucleophilic attacks. The cyano group increases the reactivity of the compound by stabilizing the electron deficiency while the amide (−CONH2) group affects its water solubility. The electron-deficient carbon adjacent to the bromine atoms plays a critical role in DBNPA’s biocidal properties, leading to the disruption of microbial cellular functions. Since DBNPA is a highly reactive molecule, it is prone to pH-dependent hydrolysis at neutral and alkaline conditions because of the weak carbon-bromide bonds. DBNPA is also susceptible to be broken down in reducing environments by stepwise debromination. Additionally, DBNPA is highly sensitive to ultraviolet (UV) exposure, which accelerates its degradation in aqueous environments. Due to its reactive nature, DBNPA must be stabilized in products to prevent premature degradation before application.
==== Sexuality ==== Hitchens was a supporter of gay rights. He opposed sodomy laws and supported same-sex marriage. He argued that the legalization of same-sex marriage was the "socialization of homosexuality" and "demonstrates the spread of conservatism" among the gay community. Hitchens was a genital integrity activist, strongly criticizing the tradition of both male circumcision and female genital mutilation. In accordance with his antitheism, Hitchens described the tolerance of metzitzah b'peh (a Jewish tradition of sucking blood from the penis after the removal of the male foreskin) as "another disgusting religious practice".
BRT Laboratories, Inc. is a Baltimore, Maryland-based biotechnology company that performs DNA testing. The company has three divisions: Relationship Testing, Forensics, and Clinical Services. It is a privately held, wholly owned subsidiary of Baltimore RH Typing Laboratory, Inc.
Sources: en.wikipedia.org
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.
The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.
It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.